

**EISAI LAUNCHES ANTICANCER AGENT LENVIMA™ IN THE UNITED STATES**  
*FIRST COUNTRY IN THE WORLD TO GAIN ACCESS TO NEW TREATMENT OPTION*

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima™ (lenvatinib mesylate) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. The United States is the first country in the world where the agent has been launched.

Discovered at Eisai's Tsukuba Research Laboratories and developed in-house, Lenvima is an orally administered molecular targeted agent that selectively inhibits the activities of several different molecules

**[Notes to editors]**

**1. About Lenvima (lenvatinib mesylate)**

Lenvima is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4)) and fibroblast growth factor